Clazosentan - Idorsia Pharmaceuticals

Drug Profile

Clazosentan - Idorsia Pharmaceuticals

Alternative Names: ACT-108475; AXV 034; AXV 034343; Pivlaz

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical; Roche
  • Developer Idorsia Pharmaceuticals
  • Class Anti-ischaemics; Dioxanes; Neuroprotectants; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebral vasospasm
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cerebral vasospasm

Most Recent Events

  • 05 Sep 2018 Idorsia Pharmaceuticals plans a phase I trial in Healthy volunteers in September 2018 (NCT03657446)
  • 23 Jul 2018 Idorsia Pharmaceuticals plans a phase I trial for Healthy Volunteers in July 2018 (NCT03596294)
  • 19 Jul 2018 Idorsia Pharmaceuticals initiates a phase I trial in Healthy volunteers in the Netherlands (IV) (NCT03596294)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top